Related Experiment Video
Updated: Oct 14, 2025
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Critical Updates on Chronic Hepatitis B Virus Infection in 2021
Cyriac A Philips1, Rizwan Ahamed2, Jinsha K Abduljaleel2
1Clinical and Translational Hepatology, The Liver Institute, Rajagiri Hospital, Aluva, IND.
Insights
Chronic hepatitis B virus (HBV) infection lacks a definitive cure, driving research into novel therapeutics and management strategies. This review details HBV biology, current treatments, and emerging therapies for chronic infection and liver failure.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B virus (HBV) infection poses a significant global health challenge, leading to severe liver conditions like cirrhosis, liver failure, and cancer.
- Despite vaccination efforts, effective treatments to eradicate chronic HBV infection remain elusive.
Purpose of the Study:
- To provide a comprehensive review of current knowledge and recent advancements in the management of chronic HBV infection.
- To explore novel therapeutic strategies and targets within the HBV lifecycle.
- To specifically address clinical updates and prognostic tools for HBV-related acute on chronic liver failure (ACLF).
Main Methods:
- Literature review of current research on HBV structure, biology, and pathogenesis.
- Analysis of updated treatment guidelines and clinical trial data for chronic HBV.
- Examination of emerging therapeutic pipelines, including vaccines and host-targeting strategies.
- Review of prognostic scores and treatment considerations for HBV-related ACLF.
Main Results:
- Current treatments for chronic HBV are evolving, with new considerations for the immune-tolerant phase and finite therapy.
- Advances in understanding HBV biology have identified novel targets for therapeutic intervention.
- Genomic research fuels hope for curative strategies like therapeutic vaccines and vector-based treatments.
- Improved prognostic tools enhance the management of HBV-related ACLF.
Conclusions:
- Significant progress is being made in understanding HBV, leading to the development of innovative therapeutic approaches.
- The future holds promise for achieving a functional cure for chronic HBV infection through targeted therapies.
- Optimized management of HBV-related ACLF is achievable with updated prognostic assessments and treatment strategies.
Abstract:
Chronic hepatitis B virus (HBV) infection is a global healthcare burden in the form of chronic liver disease, cirrhosis, liver failure and liver cancer. There is no definite cure for the virus and even though extensive vaccination programs have reduced the burden of liver disease in the future population, treatment options to eradicate the virus from the host are still lacking. In this review, we discuss in detail current updates on the structure and applied biology of the virus in the host, examine updates to current treatment and explore novel and state-of-the-art therapeutics in the pipeline for management of chronic HBV. Furthermore, we also specifically review clinical updates on HBV-related acute on chronic liver failure (ACLF). Current treatments for chronic HBV infection have seen important updates in the form of considerations for treating patients in the immune tolerant phase and some clarity on end points for treatment and decisions on finite therapy with nucleos(t)ide inhibitors. Ongoing cutting-edge research on HBV biology has helped us identify novel target areas in the life cycle of the virus for application of new therapeutics. Due to improvements in the area of genomics, the hope for therapeutic vaccines, vector-based treatments and focused management aimed at targeting host integration of the virus and thereby a total cure could become a reality in the near future. Newer clinical prognostic tools have improved our understanding of timing of specific treatment options for the catastrophic syndrome of ACLF secondary to reactivation of HBV. In this review, we discuss in detail pertinent updates regarding virus biology and novel therapeutic targets with special focus on the appraisal of prognostic scores and treatment options in HBV-related ACLF.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment